Ethamsylate PCD Pharma Franchise Company
Cafoli Lifecare offers an Ethamsylate PCD pharma franchise built on 5 formulations across tablets and injection, all manufactured at WHO-GMP certified facilities. This gives franchise partners a reliable haemostatic line for gynaecology, surgery and paediatric care.
What is Ethamsylate?
Ethamsylate is a haemostatic agent that reduces capillary bleeding by improving platelet adhesion and restoring capillary wall resistance, without acting on the coagulation cascade or causing clotting. It is used to prevent and control bleeding from small blood vessels. Read its profile on PubChem.
Therapeutic Applications
Ethamsylate is prescribed for menorrhagia and dysfunctional uterine bleeding, to prevent and control capillary bleeding in surgery, for epistaxis, and for periventricular haemorrhage in preterm neonates. Its tablet and injection forms cover both outpatient and hospital use. Prescribers include gynaecologists, surgeons, ENT specialists and neonatologists.
Why Ethamsylate is a High-Potential Molecule for Distributors
Ethamsylate is a low-cost, high-frequency haemostatic that appears in routine gynaecology prescriptions for heavy menstrual bleeding and in surgical and neonatal protocols. Menorrhagia is extremely common, giving the tablet steady outpatient turnover, while the injection secures a place on hospital and OT stock lists. That dual outpatient-plus-institutional pull makes it a steady, easy-to-move molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Etamsylate (Ethamsylate)
- PubMed: Ethamsylate literature
Our formulations of Ethamsylate find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: